for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Denali Therapeutics Inc

DNLI.OQ

Latest Trade

18.10USD

Change

-0.11(-0.60%)

Volume

600,366

Today's Range

17.66

 - 

19.09

52 Week Range

13.78

 - 

28.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.21
Open
18.13
Volume
600,366
3M AVG Volume
6.21
Today's High
19.09
Today's Low
17.66
52 Week High
28.84
52 Week Low
13.78
Shares Out (MIL)
95.84
Market Cap (MIL)
1,745.28
Forward P/E
-8.78
Dividend (Yield %)
--

Latest Developments

More

Denali Therapeutics Inc Reports Quarterly Loss Per Share Of $0.61

Denali Therapeutics Receives Orphan Drug And Rare Pediatric Disease Designation For Dnl310

Denali Therapeutics Says Collaboration Revenue Was $4.2 Mln For Three Months Ended March 31, 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Denali Therapeutics Inc

Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.

Industry

Biotechnology & Drugs

Contact Info

161 Oyster Point Blvd

+1.650.8668548

https://www.denalitherapeutics.com

Executive Leadership

Vicki L. Sato

Independent Chairman of the Board

Ryan J. Watts

President, Chief Executive Officer, Co-Founder, Director

Alexander O. Schuth

Co-Founder, Chief Operating Officer, Secretary

Steve Krognes

Chief Financial Officer, Treasurer

Carole Ho

Chief Medical Officer and Head of Development

Key Stats

2.20 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.1K

2019(E)

0.0K
EPS (USD)

2017

-5.890

2018

-0.390

2019(E)

-2.075
Price To Earnings (TTM)
--
Price To Sales (TTM)
12.90
Price To Book (MRQ)
3.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-9.75
Return on Equity (TTM)
-9.12

Latest News

BRIEF-Denali Therapeutics Reports Qtrly Net Loss Per Share $0.74

* DENALI THERAPEUTICS ANNOUNCES FIRST-IN-HUMAN DOSING OF ITS RIPK1 INHIBITOR CLINICAL PROGRAM AND THE APPOINTMENT OF PETER KLEIN TO BOARD OF DIRECTORS; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BRIEF-Temasek Holdings Dissolves Share Stake In Marin Software, Takes Share Stake In Denali Therapeutics

* TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN MARIN SOFTWARE INC - SEC FILING

BRIEF-Denali Therapeutics, Lonza Pharma & Biotech Announce Exclusive Partnership To Develop And Produce Biologic Medicines

* DENALI THERAPEUTICS AND LONZA PHARMA & BIOTECH ANNOUNCE EXCLUSIVE PARTNERSHIP TO DEVELOP AND PRODUCE BIOLOGIC MEDICINES

BRIEF-Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases

* TAKEDA AND DENALI THERAPEUTICS COLLABORATE TO DEVELOP AND COMMERCIALIZE THERAPIES FOR NEURODEGENERATIVE DISEASES

BRIEF-Denali Therapeutics Now Sees IPO Of 13.9 Million Shares Priced Between $17-$19 Per Share

* DENALI THERAPEUTICS INC SEES IPO OF 13.9 MILLION SHARES OF ITS COMMON STOCK PRICED BETWEEN $17.00 AND $19.00 PER SHARE - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up